Klipper22
07-23-2007, 09:30 PM
This used to be EXEG. The move to the AMEX brought about a name change. Chart just took off again today making a run back at $5.
http://stockcharts.com/h-sc/ui?s=OPK&p=D&yr=1&mn=0&dy=0&id=p10978200228&listNum=1&a=96964603
Opko Health, Inc.
4400 Biscayne Boulevard
Suite 900
Miami, FL 33137
United States - Map
Phone: 305-575-6015
Fax: 305-575-6049
DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Drug Manufacturers - Other
Full Time Employees: 17
BUSINESS SUMMARY
Opko Health, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment and prevention of ophthalmic disorders and diseases. Its product candidates include bevasiranib sodium, which completed a Phase II clinical trial for the treatment of wet age-related macular degeneration (Wet AMD) and diabetic macular edema. The company is also developing product candidates for the treatment of Wet AMD, which target other pathways involved in the pathogenesis of Wet AMD, including hypoxia-inducible factor 1 alpha. In addition, it is developing products for the treatment of dry age-related macular degeneration and retinitis pigmentosa diseases. Opko Health has collaboration and license agreements with University of Pennsylvania, Intradigm Corporation, Pathogenics, Inc., University of Illinois, ZaBeCor Pharmaceutical Company, LLC, and University of Florida Research Foundation. The company was founded in 2006 and is based in Miami, Florida.
Shares Outstanding: 113.12M
Float: 90.01M
http://stockcharts.com/h-sc/ui?s=OPK&p=D&yr=1&mn=0&dy=0&id=p10978200228&listNum=1&a=96964603
Opko Health, Inc.
4400 Biscayne Boulevard
Suite 900
Miami, FL 33137
United States - Map
Phone: 305-575-6015
Fax: 305-575-6049
DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Drug Manufacturers - Other
Full Time Employees: 17
BUSINESS SUMMARY
Opko Health, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment and prevention of ophthalmic disorders and diseases. Its product candidates include bevasiranib sodium, which completed a Phase II clinical trial for the treatment of wet age-related macular degeneration (Wet AMD) and diabetic macular edema. The company is also developing product candidates for the treatment of Wet AMD, which target other pathways involved in the pathogenesis of Wet AMD, including hypoxia-inducible factor 1 alpha. In addition, it is developing products for the treatment of dry age-related macular degeneration and retinitis pigmentosa diseases. Opko Health has collaboration and license agreements with University of Pennsylvania, Intradigm Corporation, Pathogenics, Inc., University of Illinois, ZaBeCor Pharmaceutical Company, LLC, and University of Florida Research Foundation. The company was founded in 2006 and is based in Miami, Florida.
Shares Outstanding: 113.12M
Float: 90.01M